In contrast to our findings, Mohyeddin Bonab et.al observed no substantial change in the serum levels of IL-4, IL-10, and TGF-β during the 12-month follow-up after intrathecal administration of autologous BM-MSCs in patients suffering from MS [16]. The gene discussed is TGFB1; the disease is myeloid sarcoma.